Design and Development of a Behaviorally Active Recombinant Neurotrophic Factor

Area of Science:

• Neuroscience
• Biochemistry
• Drug Discovery

Background:

• Carbamoylated erythropoietin (CEPO) exhibits antidepressant and pro-cognitive effects by increasing neurotrophic factors like BDNF.
• Current CEPO production is challenging due to reliance on pure EPO, scalability issues, and batch variability.

Purpose of the Study:

• To design and develop a recombinant mimetic of CEPO, named QPO, that overcomes production limitations while retaining therapeutic effects.
• To investigate QPO's mechanism of action, including its interaction with the EPOR receptor and its effect on BDNF expression.

Main Methods:

• Computational structural biology, molecular, cellular, and behavioral assays were used to design, produce, purify, and test QPO.
• In-silico binding affinity analysis of QPO with the EPOR/EPOR homodimer receptor.

Main Results:

• QPO demonstrated nonhematopoietic properties and significant antidepressant-like and pro-cognitive effects in rodent models.
• QPO upregulated BDNF expression both in vitro and in vivo.
• In-silico analysis revealed decreased binding of QPO to Active Site 2 of the EPOR receptor, suggesting a potential role in neuroactive signaling.

Conclusions:

• QPO is a successful CEPO mimetic with potential therapeutic applications for psychiatric disorders.
• The findings suggest QPO may act via a neurotrophic mechanism similar to CEPO.
• The importance of glutamine residues for QPO's activity was confirmed, as substituting them with arginine (RPO) abolished behavioral effects.